川芎嗪治疗失代偿期慢性肺心病的临床研究

Self-contrasted method was used in observing 49 patients with advanced cor pulmonale.They were divided into two groups,A and B groups（A group:control period followed by course of treatment;B group:vice versa）.Before and after intravenous administration of ligustrazini（120 mg）,pulmonary hemodynamic,right cardiac function,hemorheology and arterial blood gas were determined in these patients.After one course of treatment,A and B group showed that:Pap decreased by 6.84 and 6.73 mmHg respectively.PVR lowered for 87.08 and 71.34 dyn·s·cm⁵,CO elevated for 1.05 and 1.23 L/min.,HR reduced for 7.9 and 6.8 beats/min.,Q-B interval shortened for 0.03 and 0.03 sec.,B-Y interval prolonged for 0.03 and 0.05 sec.,Q-B/B-Y ratio,Q-BI and B-YI improved,H_S elevated by 0.05 and 0.06 Ω,α time prolonged by 0.02 and 0.03 sec.;the whole blood viscosity（high）decreased for 1.36 and 1.20,whole blood viscosity（low）reduced for 4.27 and 4.19;plasma viscosity lowered for 0.66 and 0.43,RBC electrophoretic time shortened by 6.74 and 6.34 sec.,hematocrit decreased for 6.92 and 3.75% respectively.These changes of parameters were significant in the course of treatment with ligustrazini（P<0.05～0.01）,but not significant in the control period of treatment.Arterial blood gas changes were observed in 6 patients.After treatment with ligustrazini,results showed that the PaCO₂ was significantly reduced from 65.2±10.0 to 61.3±8.5 mmHg （P<0.05）.Except that,the pH,PaO₂ and SaO₂ did not significantly change.These results showed the ligustrazini was effective in"promoting the blood circulation and removing the blood stasis",namely,in dilating the pulmonary vessels,decreasing Pap and PVR,and improving right cardiac function as well as hemorheological quality in treating patients with cor pulmonale.

关闭